Trial Profile
A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms GOLD
- Sponsors AstraZeneca
- 31 Mar 2023 Status changed from active, no longer recruiting to completed.
- 20 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 17 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.